Xencor Reports Positive Phase 1 XmAb942 Data and Preclinical XmAb412 Results, Advancing TL1A Franchise for Autoimmune Diseases
XNCR sits 94% above its 52-week low of $6.92.
Summary
Xencor announced positive final Phase 1 data for XmAb942 and strong preclinical results for XmAb412, bolstering its TL1A pipeline for autoimmune diseases and supporting advanced clinical development.
Key Events · Product Development and Regulatory · XNCR
-
XmAb942 Phase 1 Final Results Positive
The Phase 1 study of XmAb942 in healthy participants showed it was safe and well-tolerated, with an estimated terminal half-life of 74.1 days supporting a 12-week maintenance dosing interval. The drug demonstrated favorable immunogenicity and is predicted to achieve superior TL1A inhibition compared to first-generation antibodies.
-
XmAb412 Preclinical Data Supports Novel Bispecific
Preclinical characterization of XmAb412, a TL1A x IL23p19 bispecific antibody using the novel XenLock™ platform, showed robust suppression of both inflammatory pathways and a predicted human half-life of 60-70 days. A first-in-human study is expected to begin in Q3 2026.
-
TL1A Franchise Positioned for Growth
Xencor is advancing its TL1A portfolio, positioning XmAb942 and XmAb412 as potentially best-in-class treatments for inflammatory bowel disease and other autoimmune diseases, with key clinical milestones expected through 2027.
Analysis · XNCR · Life Sciences
Xencor has reported final positive Phase 1 results for XmAb942, an anti-TL1A antibody, demonstrating a favorable safety profile, extended half-life supporting a 12-week dosing interval, and superior immunogenicity compared to first-generation competitors. This data significantly de-risks the ongoing Phase 2b XENITH-UC study for ulcerative colitis. Additionally, strong preclinical data for XmAb412, a novel TL1A x IL23p19 bispecific antibody utilizing the XenLock™ platform, positions it for a first-in-human study in Q3 2026. These updates reinforce Xencor's strategy to develop a best-in-class TL1A franchise, addressing a large and growing market in inflammatory bowel disease and other autoimmune conditions, which could drive future growth and partnerships.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 44.9% of the 1407 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XNCR was trading at $13.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $979.8M. The 52-week trading range was $6.92 to $18.69. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.